Swedish and Nativis Partner in First Human Clinical Trial to Disrupt Cancer Cell Division

April 29, 2015

Swedish’s Ben & Catherine Ivy Center for Advanced Brain Tumor Treatment launches new clinical trial to treat brain cancer with the Nativis Voyager Radio Frequency Energy (RFE) Medical Device

SEATTLE, April 29, 2015 – The Swedish Neuroscience Institute’s Ben & Catherine Ivy Center for Advanced Brain Tumor Treatment today announced a new clinical trial for treating brain cancer. The trial (ID no. NCT02296580 – “A Feasibility Study of the Nativis Voyager System in Patients with Recurrent Glioblastoma Multiforme”), sponsored by Nativis, Inc. in Seattle – will investigate the safety and efficacy of the Nativis Voyager RFE medical device in humans. The device has shown promise in preclinical studies.

"This technology has been in development for more than a decade," said John Butters, Chairman, President and CEO of Nativis." We are proud to be partnering in this clinical trial with Dr. Charles Cobbs, and the world-class teams of Neurosurgeons and Neuro-oncologists at Swedish."

Nativis Voyager is a non-invasive investigational medical device that emits low-level, non-thermal, non-ionizing radio frequency energy to disrupt the division of cancer cells. The device consists of a lightweight headband that is connected via cable to a pager-sized controller; patients wear the Nativis Voyager for 24 hours per day for the prescribed time period.

Eleven patients will participate in the clinical trial. Additional trials will begin once the safety of the Nativis Voyager RFE System in humans is established. Nativis Voyager RFE System is an investigational device and is not yet approved by the U.S. Food and Drug Administration (FDA).

"Nativis Voyager is a potentially revolutionary cancer therapy," said Dr. Charles Cobbs, MD, Medical Director of the Ivy Center. "At the Ivy Center, we are dedicated to pursuing research that could make a difference in the lives of patients with Glioblastoma."

Glioblastoma Multiforme (GBM) is the most common primary malignant brain tumor and one of the most fatal known to humankind. GBM affects 22,000 people nationwide, including about 600 people in Washington state. A typical survival rate is about 16 months.

###

About The Ben & Catherine Ivy Center for Advanced Brain Tumor Treatment
Opened in 2008, the Ben & Catherine Ivy Center for Advanced Brain Tumor Treatment gives patients with brain tumors and their families access to a unique multidisciplinary team of skilled neurosurgeons, oncologists, radiologists and a specialized nursing staff who deliver coordinated care and innovative treatments for both benign and malignant brain tumors. The Ivy Center’s unique design places its world-class research facility directly adjacent to the outpatient clinic, providing patients with immediate access to promising new therapies. As part of the Swedish Neuroscience Institute located in Swedish Medical Center’s Cherry Hill Campus, the Ivy Center is the first brain tumor-specific, community-based facility of its kind in the Pacific Northwest and is providing new hope for patients with all stages of brain tumors, including brain cancer. The Ivy Center was created through a grant from The Ben & Catherine Ivy Foundation, based in Scottsdale, Ariz. (www.ivyfoundation.org).

About Nativis, Inc.
Nativis is a clinical stage bioelectronics company developing technology-based therapies for cancers and other serious illnesses. At the interface of chemistry and physics, Nativis’s proprietary Radio Frequency Energy (RFE) technology regulates defined bioactive targets through the modulation of charge pathways. RFE modulated control of charge pathways has the potential to significantly change the way cancer and other serious diseases are treated. Nativis is located in Seattle, Washington.